Europe Leukapheresis Market

The report "Europe Leukapheresis Market by Product (Devices, Disposable, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Forecast to 2031" is projected to grow from USD 24.2 million in 2026 to USD 34.1 million by 2031, at a CAGR of 7.1% from 2026 to 2031.

Browse 180 market data Tables and 69 Figures spread through 300 Pages and in-depth TOC on "Europe Leukapheresis Market, by Product (Devices, Disposable, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/europe-leukapheresis-market-143716897.html

The Europe leukapheresis market is witnessing a steady growth due to the growing incidence of hematology disorders and the deployment of apheresis procedures as a routine practice. Additionally, the trend is shifting from hospital-based procedures toward outpatient facilities and specialized apheresis centers, enhancing the potential and capabilities for procedures. The growing inclusion of European hospital systems in large-scale international research and continuous government investment in gene and cellular therapy research also fuel the market. In addition, the regulatory requirements in the European market encourage the use of disposable products.

Disposables segment accounted for the largest share of the Europe leukapheresis market in 2025

In the Europe region, the disposables type segment dominated the leukapheresis market in 2025, as there was an increased focus on standardized procedures and end-to-end traceability in the healthcare sector. Disposables are supportive of strict regulations and are ideal for cell and gene therapy sample collection procedures, where uniformity, safety, and documentation of handling of the sample are of high importance. Changes in protocols, multi-site clinical trials, and re-procedures related to CGT collections will sustain demand for disposable products, thus ensuring that this segment remains the core source of revenue in the European market.

Academic & research institutes segment is projected to register the highest CAGR  between 2026 and 2031

By end user, the academic & research institutes segment is expected to register the highest CAGR in the Europe leukapheresis market during the forecast period. This can be attributed to an increase in activity related to cell and gene therapy. There has been an increase in publicly funded programs, as well as an increase in partnerships with the biotech community, driving the market for cells derived through leukapheresis. These facilities are an essential part of early-phase research and thus contribute to sustaining growth.

UK is anticipated to grow at the fastest rate during the forecast period

The UK is projected to exhibit the highest CAGR in the Europe leukapheresis market during the forecast period, largely due to its comparatively mature, NHS-integrated cell therapy ecosystem that drives steady demand for leukapheresis as a starting-material collection step. This includes strong national infrastructure, such as NHS Blood and Transplant’s established apheresis network and the growing number of NHS-commissioned CAR-T treatment centers, supported by the Cell and Gene Therapy Catapult and ATTC programs, which together sustain high leukapheresis demand.

Major players in the Europe leukapheresis market include Fresenius Kabi (Germany), Terumo BCT (Japan), Haemonetics Corporation (US), Grifols S.A. (Spain), Macopharma (France), Medica S.p.A. (Italy), Miltenyi Biotec (Germany), Baxter International Inc. (US), Nikkiso Co., Ltd. (Japan), Immune Therapy Holdings AB (Sweden), SCTbio (Czech Republic), Biohope Scientific SL (Spain), and Caltag Medsystems Ltd. (UK).

Don’t miss out on business opportunities in Keyword. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/